ZEPP — Zepp Health Corporation

Summary of Zepp Health Corporation Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $51.5 million, up 33.8% year-over-year, aligning with guidance.
• Gross Margin: 37.7%, a slight increase of 0.4% year-over-year but down from 40.4% in Q4 2025.
• Gross Profit: Increased by 35.3% to $19.4 million.
• Operating Loss: Narrowed to $6.3 million from $17.2 million in Q1 2025.
• Adjusted Net Loss: $17.9 million, or 34.8% of sales, improved from 41% in Q1 2025.
• Cash and Cash Equivalents: $103.2 million, down from $112.9 million at the end of 2025.
• Inventory: Reduced to $62.8 million from $72.8 million in Q4 2025.

2. Strategic Updates and Business Highlights

• Product Launches: Successful launches of Amazfit Active Max, Active 3 Premium, and T-Rex Ultra 2 contributed to revenue growth.
• Premiumization Strategy: Average selling price increased by over 20% year-over-year, with premium models accounting for nearly 50% of T-Rex family sales.
• Partnership with HYROX: A new 3-year global partnership aimed at enhancing the hybrid training experience and establishing brand authority in this emerging category.
• Market Position: Achieved top 6 smartwatch brand status in the U.S. and Europe by value share, reflecting strong market resonance.

3. Forward Guidance and Outlook

• Q2 Revenue Guidance: Expected to be between $63 million and $68 million, representing year-over-year growth of 6% to 14%.
• Focus on Quality Growth: Emphasis on product mix, pricing power, and user engagement rather than solely on revenue volume.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressures: Facing headwinds from rising memory component costs and unfavorable foreign currency fluctuations.
• Operating Expenses: Increased to $35.7 million from $31.5 million in Q1 2025, driven by foreign exchange impacts and front-loaded marketing investments.
• Product Launch Timing: Potential delays in product launches could impact revenue forecasts, with some products possibly slipping into Q3.

5. Notable Q&A Insights

• Product Launches: CFO Leon Deng confirmed expectations for more than 9 product launches in 2026, with several already announced.
• Cost Management: There are opportunities to reduce R&D and marketing expenses in the second half of the year as product launches stabilize.
• Competitive Pricing: Competitors are also raising prices to offset higher costs, but Zepp Health maintains a relatively lower pricing strategy, allowing for potential price increases without losing competitiveness.

This summary encapsulates the key points from Zepp Health's Q1 2026 earnings call, highlighting both the positive developments and the challenges the company faces moving forward.